How has Novacyt ROCE changed compared to the previous year?

Return on Capital Employed (ROCE) of Novacyt changed from -16.18 % to -31.01 %, representing a 91.62% change. The value is lower than the previous year.

How has Novacyt ROCE developed historically?

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Novacyt since 2006 – with annual values, charts, and detailed analysis.

What is the Novacyt ROCE?

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Novacyt with sector peers and the industry average to assess whether it is attractive.

How does Novacyt ROCE compare to the industry average?

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Novacyt ROCE

ALNOV.PA

The Return on Capital Employed (ROCE) of Novacyt (ALNOV.PA) as of Jul 15, 2026 is -31.01 %. In the previous year, Return on Capital Employed (ROCE) was -16.18 % — a change of 91.62% (lower).

Get this data via API

Financial Data API

ROCE

-31.01 %

YoY

91.62%

Last updated: Jul 15, 2026

In 2026, Novacyt's return on capital employed (ROCE) was -31.01 %, a 91.62% increase from the -16.18 % ROCE in the previous year.

Access this data via the Eulerpool API

Docs Get Free API Key

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Novacyt's Return on Capital Employed (ROCE)

Novacyt's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Novacyt's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Novacyt's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Novacyt’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Novacyt ROCE

Novacyt Stock analysis

ROCE Details

Unraveling Novacyt's Return on Capital Employed (ROCE)

Year-to-Year Comparison

Impact on Investments

Interpreting ROCE Fluctuations

Frequently Asked Questions about Novacyt stock

What is the Novacyt ROCE 2026?

How has Novacyt ROCE changed compared to the previous year?

How has Novacyt ROCE developed historically?

What is the Novacyt ROCE?

What is a good ROCE?

How does Novacyt ROCE compare to the industry average?

Profitability — Novacyt

All Key Metrics — Novacyt

Valuation

Income Statement

Margins

Balance Sheet

Cash Flow

Profitability

Leverage

Growth

Dividend

Workforce

Quality

Other